NOT FDA-APPROVED

BPC-157

A small lab-made peptide that's become the most-talked-about name in injury recovery research. Here's what it actually is, why people are excited about it, and what the science honestly says.

The 30-second read

BPC-157 is a synthetic peptide that researchers have studied for tissue repair, tendons, ligaments, gut lining, muscle. It comes up constantly in conversations about stubborn injuries that won't heal. Most of the evidence comes from animal studies, where the results are remarkably consistent. Human evidence is much thinner: about three small pilot studies. The FDA has not approved it for any use, and as of 2023 it can't be made by licensed compounding pharmacies in the U.S. Interesting enough that researchers and clinicians are paying close attention. Early enough that the honest answer to "does it work in people?" is "we don't actually know yet."

Why this peptide is on people's radar

BPC-157 went from an obscure research compound to a household name through a pretty specific pipeline: athletes started naming it on podcasts, mainstream press picked up the recovery angle, and a wave of people with injuries that wouldn't heal started asking their doctors about it.

Jeremy Renner mentioned BPC-157 as one of the peptides he used during his recovery from the snowplow accident that broke 30 of his bones. Joe Rogan made the BPC-157 + TB-500 "Wolverine stack" a recurring topic on his podcast. HHS Secretary Robert F. Kennedy Jr. has publicly pushed for compounding access to be restored, and in April 2026 the FDA agreed to convene an advisory panel to do exactly that review.

The attention isn't out of nowhere. There are over a thousand published preclinical studies suggesting BPC-157 speeds up healing in tendons, ligaments, gut tissue, and muscle in animal models. The mechanisms are interesting. The animal results are consistent across labs. What hasn't happened yet is the part where rigorous human trials confirm any of it, and that's the gap researchers and clinicians are watching closely.

What people are usually trying to do with it

The reasons people end up reading about BPC-157 tend to fall into a few buckets:

Heal a tendon, ligament, or muscle injury that hasn't gotten better with rest and physical therapy
Calm an unhappy gut, reflux, IBS-type symptoms, gastritis, NSAID damage
Bounce back faster from surgery or a training-related tear
Quiet down a joint that keeps flaring up
Generally feel like the body recovers the way it used to

What the science actually shows

Here's a plain-English summary of what published research has actually demonstrated. Almost all of it comes from animal studies, that's important context. Footnote numbers link to the source.

Tendon and ligament healing

Rat studies of Achilles tendon injury have repeatedly shown faster healing and stronger repaired tissue when BPC-157 is given.3 5 No human randomized trials yet.

Gut and stomach lining protection

Animal studies show protection against ulcers caused by NSAIDs and stress, plus faster healing of gut-lining damage.1 7 Human trials for IBD or ulcers haven't been done.

Anti-inflammatory effects

In multiple animal injury models, BPC-157 lowered the markers we associate with inflammation. The clinical meaning of that in humans is unproven.7

Muscle and nerve recovery

Rat models of muscle tears and crushed nerves show faster recovery. Like the rest, none of this has been replicated in proper human studies.6

What it has not been shown to do

Cure chronic injuries in humans. Reliably treat any specific medical condition. Be safe over months or years of use. None of those have human evidence behind them.

The honest read

What's solid:

The animal evidence for tissue repair is unusually consistent, over a thousand preclinical studies from multiple labs point in the same direction for tendons, gut, and muscle.

What's still unproven:

The human side. There are about three small pilot studies, all from one Florida research group, with no proper randomized controlled trials. We do not have human safety data beyond a few weeks, and we do not have rigorous proof of effectiveness in people.

What's hyped beyond the evidence:

Claims that BPC-157 reliably heals chronic injuries in humans, that the WOLVERINE stack is medically established, or that long-term use is proven safe. Those are extrapolations from animal data and personal stories, not the same as clinical proof. They might turn out to be right. The honest position today is "we don't know yet."

Things to know if you're looking into it

How it's usually used in research: a small daily injection of liquid into the fat layer under the skin, typically the belly. Some protocols try oral capsules, but whether the oral version reaches the bloodstream in any useful way is genuinely unclear.
Regulatory status: not FDA-approved. As of September 2023, it can't be legally compounded by licensed pharmacies in the U.S. There's an FDA advisory panel review scheduled for July 2026 that could change the compounding picture.
Athletes: BPC-157 is on the World Anti-Doping Agency banned list and the NCAA's prohibited substances list. Competitive athletes will test positive.
Reported tolerability: in the small studies that exist, people generally tolerated it well in the short term. The studies were too small and short to catch rare or long-term issues.
Healthcare provider involvement: a licensed clinician should be part of any decision about use. This site doesn't make personalized recommendations and doesn't replace a doctor.
Specific dosing protocols, mechanism details, half-life, and stacking: all of that lives in the "Want to go deeper?" section below, kept out of the way for casual readers, available if you want it.

Reconstitution & dose calculator

Not FDA-approved. BPC-157 is on the FDA's Category 2 bulks list (Sept 2023), which means licensed U.S. pharmacies can't compound it. Human dose-finding studies don't exist; the numbers below summarize what small published pilots and the research community have used. This calculator is an educational reference, not dosing guidance.

Suggested start

250 mcg/day

Lower end of pilot-study range

Common range

250–500 mcg/day

Often split AM/PM

Max dose

500 mcg/day

Upper bound of pilot data

Cycle

4–8 wks on

Then 2–4 weeks off

Vial size

Bacteriostatic water

mL

Defaults to a 5 mg/mL dilution — gives more precision on the syringe at microgram doses. Adjust to taste.

Daily dose

mcg

Subcutaneous injection (typically into belly fat). Often split into AM and PM doses.

Concentration

5.0 mg/mL

Per dose

0.05 mL

5 units on insulin syringe

Doses per vial

~40

~40 days (~5.7 weeks) of daily dosing

When to stay put vs. escalate

Stay put when you're seeing improvement at the current dose, when you're within the first two weeks of starting (effects on tendon and connective tissue can take time to register), or when 250 mcg/day is producing the response you're after. There's no titration-tolerance dynamic here — staying low is generally fine if it's working.

Consider going to 500 mcg/day only after at least four weeks at 250 mcg/day with no perceptible improvement and no side effects. Going above 500 mcg/day exits the published pilot range entirely, and there's no human data on safety or effectiveness at higher doses.

Cycle off at the 4–8 week mark regardless of progress. Long-term continuous use hasn't been studied in humans. The 2–4 week off-period pattern is community wisdom rather than evidence-based, but it errs on the side of caution given how thin the long-term safety data is.

For educational and research purposes only. This is not medical advice. BPC-157 is not FDA-approved and is on the FDA Category 2 bulks list. Athletes: it is on the WADA and NCAA banned lists. Consult a licensed healthcare provider before any health decision.

What people often ask

Is BPC-157 safe?

The honest answer is "we don't have enough data to say." The handful of small human studies reported it was tolerated well over a few weeks, but those studies were too small to catch uncommon or long-term issues. Long-term safety in humans is unknown.

Is BPC-157 legal in the U.S.?

It's not FDA-approved, and since September 2023 licensed compounding pharmacies can't legally make it. An FDA advisory panel is reviewing whether to change that in July 2026, but as of today the legal pathway is restricted.

Does it actually heal injuries?

In animal studies, repeatedly, yes. In rigorous human trials, those haven't been done. Anecdotal reports from patients and athletes are encouraging but they aren't the same thing as clinical evidence.

What's the "Wolverine stack"?

It's a nickname for combining BPC-157 with TB-500, another peptide studied for tissue repair. The idea is that they cover different parts of the healing process. There are zero published human studies of that combination, so any claims about its effectiveness are extrapolations.

Can you take it as a pill?

Some research has explored oral versions because BPC-157 is naturally found in stomach juice and may survive stomach acid. Whether enough actually reaches the bloodstream to do anything is not clear from existing studies.

Will competitive athletes test positive?

Yes. BPC-157 is on the World Anti-Doping Agency banned list and the NCAA's prohibited substances list as of 2024.

Why is there so much animal data and so little human data?

Because nobody has run proper human trials. Running a real clinical trial costs millions of dollars and requires regulatory engagement that a small academic lab can't usually fund. No major drug company has taken it on, partly because of the regulatory status.

FDA and regulatory status

⚡ Regulatory update. April 15, 2026

The FDA announced it will convene the Pharmacy Compounding Advisory Committee on July 23–24, 2026 to review whether BPC-157 (free base and acetate forms) should be removed from the Category 2 list and made available for compounding. This follows public advocacy from HHS Secretary Robert F. Kennedy Jr. The panel's recommendation is advisory; the FDA retains final decision authority. Sources: FDA.gov, STAT News, NBC News.

Status as of May 5, 2026: Not FDA-approved for any medical indication in humans. Added to the FDA Category 2 list in September 2023, which makes it ineligible for compounding by licensed pharmacies under Sections 503A and 503B. Not approved in the EU, UK, Canada, Australia, or Japan. No phase II or phase III trials are registered on ClinicalTrials.gov as of this date. Status updates land here when they happen.

Notable commentary

A few of the public conversations that pushed BPC-157 into the mainstream. These are personal accounts and policy statements, not clinical evidence.

"Everyday, countless hours of physical therapy, peptide injections, iv drips and pushes, stem cell and exosomes, red light / IR therapy."

Jeremy Renner, in a 2023 Instagram post detailing his recovery regimen following the January 2023 snowplow accident in which he broke 30 bones. Renner has publicly named BPC-157, Thymosin Alpha-1, Thymosin Beta-4, and MOTS-c as peptides in his recovery protocol. Coverage in NBC News, The Hollywood Reporter, and Today.com.

Personal anecdote, not clinical evidence. For educational purposes only.

Joe Rogan and the "Wolverine stack"

Podcaster Joe Rogan is widely credited with pulling BPC-157 and the BPC-157 / TB-500 "Wolverine stack" into mainstream awareness through repeated discussion on The Joe Rogan Experience. Mainstream coverage has noted his influence while flagging that human clinical evidence remains limited.

Personal anecdote and media commentary, not clinical evidence. For educational purposes only.

HHS Secretary Robert F. Kennedy Jr.

"The FDA has a job: do the science and tell the public what they've learned."

On The Joe Rogan Experience #2461 (Feb 27, 2026), HHS Secretary Kennedy described the FDA's role in plain terms and signaled support for restoring compounding access for several research peptides, BPC-157 among them. Coverage: NPR · MIT Technology Review

Policy statement, not FDA approval or clinical evidence. Reclassification, if it happens, would expand compounding access, it would not establish efficacy or safety. For educational purposes only.

Reality check: Celebrity endorsements and political announcements are not clinical evidence. BPC-157 has roughly three small published human pilot studies and extensive animal data. Regulatory reclassification, if it occurs, would expand compounding-pharmacy access, not FDA approval.

Want to go deeper? Mechanism, half-life, studied dosing, stacking, clinical trial detail, and full reference list. Click to expand.

Background and discovery

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a protective protein found in human gastric juice. Its amino acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It was isolated and characterized by a research group at the University of Zagreb in the 1990s while studying cytoprotective factors naturally present in the stomach.

Over a thousand preclinical studies have been published since, examining BPC-157's effects across organ systems including tendon and muscle repair, gastrointestinal healing, and neuroprotection. Human clinical evidence remains extremely limited, roughly three small pilot studies from a single research group based in Florida.

Mechanism of action

All proposed mechanisms are derived from preclinical research in cultured cells and animal models. Hypotheses include:

Nitric oxide (NO) system modulation

Animal wound-healing models report increased expression of endothelial nitric oxide synthase (eNOS) following BPC-157 administration. The NO pathway supports tissue repair through vasodilation and angiogenesis.

Growth factor upregulation

Preclinical research indicates BPC-157 may increase expression of EGF, VEGF, and FGF in injured tissues. These factors are central to cell proliferation, differentiation, and angiogenesis.

FAK-paxillin pathway activation

Some in-vitro and animal studies suggest BPC-157 activates the focal adhesion kinase (FAK)-paxillin signaling pathway, involved in cell migration and extracellular matrix remodeling.

Anti-inflammatory signaling

Multiple preclinical studies report reductions in IL-6, TNF-α, and IL-8 in injured tissues following BPC-157 treatment, possibly via NF-κB modulation.

GI cytoprotection

Animal studies demonstrate gastroprotection against NSAID-, alcohol-, and stress-induced gastric injury, attributed to improved mucus production and epithelial integrity.

Critical limitation: No human mechanistic studies have confirmed any of these pathways are activated in human tissues at any dose or duration.

Commonly studied dosing protocols

These are not recommendations. The ranges below describe what has appeared in published research and discussed protocols. Safe and effective doses in humans have not been established. Always consult a licensed healthcare provider.

Subcutaneous (research range)

Rodent studies typically use 1–10 mcg/kg/day. Allometric scaling suggests a 70 kg human equivalent of roughly 200–500 mcg/day, although this conversion has not been validated in human dose-finding studies. The small published human pilot studies have used 250–500 mcg/day, often split AM/PM.

Oral / sublingual (research range)

Some research has explored oral administration in the 250–500 mcg/day range based on the theory that BPC-157 may resist gastric degradation. Human pharmacokinetic data for oral BPC-157 does not exist.

Treatment duration

Reported research durations range from 4 to 12 weeks. Some protocols use a "cycle" approach (6–8 weeks on, then break). Long-term safety has not been studied.

Reconstitution (for the math)

A 5 mg vial reconstituted with 2 mL bacteriostatic water yields 2.5 mg/mL. A 250 mcg dose at that concentration is 0.1 mL, which is 10 units on a U-100 insulin syringe. See the reconstitution guide for the full formula and worked examples.

Half-life and pharmacokinetic timing

Pharmacokinetics in humans have not been formally studied. Animal studies suggest a relatively short plasma half-life, minutes to a few hours, which is the rationale behind twice-daily dosing in many research protocols. The peptide's actual tissue distribution, metabolism, and elimination in humans are unknown.

Side effects and safety profile

Safety data is extremely limited. The absence of reported adverse effects reflects the small amount of research conducted, not proof of safety.

Reported in research / community settings

Mild injection-site redness or swelling (anecdotal)
Mild nausea (anecdotal, often resolves with empty-stomach administration)
Lightheadedness or transient dizziness (anecdotal)
Mild fatigue (anecdotal)

Theoretical concerns

Because BPC-157 promotes angiogenesis and growth-factor signaling in animal models, theoretical concerns exist about effects on tumor biology. There are no reports of tumor promotion, but the question has not been studied. Chronic suppression of inflammatory signaling is similarly an open theoretical concern.

Long-term safety

No studies extend beyond about 12 weeks. Tolerance, immunological reactions, and effects on growth-factor signaling over longer timeframes are unknown.

Stacking considerations

BPC-157 + TB-500 ("Wolverine stack"): the most-discussed combination. The theoretical case is that BPC-157 supports angiogenesis and growth-factor signaling while TB-500 facilitates cell migration. Reported community dosing pairs 250–500 mcg/day BPC-157 with 2–5 mg/week TB-500. There are zero published human studies of this combination.

BPC-157 + GHK-Cu ("Glow blend"): sometimes paired in skin-and-connective-tissue contexts, with GHK-Cu contributing collagen-remodeling effects in preclinical work. No published human studies of the combination.

General considerations: any combination introduces theoretical interaction concerns, overlapping mechanisms, additive effects, immunological reactions. None of this has been characterized in humans.

Clinical trial status and the preclinical–clinical gap

As of May 2026, BPC-157's evidence base is unusually skewed: roughly 1,000+ preclinical publications versus about three small human pilot studies (all from one Florida research group, with sample sizes of 20–30, no proper blinding, and short follow-up).

A search of ClinicalTrials.gov shows no active, recruiting, or completed BPC-157 trials. No major pharmaceutical company has announced a development program. The likely drivers of this gap are regulatory (Category 2 listing eliminated commercial compounding pathways), commercial (no clear path to a return on a multi-million-dollar trial program), and structural (academic groups generating the preclinical data lack the funding for full clinical development).

References

Sikiric, P., Seiwerth, S., Grabarevic, Z., et al. (1997). "Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model." Life Sciences, 60(21), 1923–1935. PubMed
Sikiric, P., Seiwerth, S., Grabarevic, Z., et al. (1999). "Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications." J Physiol Pharmacol, 50(3), 383–394. PubMed
Staresinic, M., Sikiric, P., Anic, T., et al. (2003). "Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon." J Orthop Res, 21(2), 976–983. PubMed
Seiwerth, S., Sikiric, P., Blagaic, A., et al. (1999). "BPC 157's effect on healing of transected rat Achilles tendon." J Physiol Paris, 93(3-4), 311–315. PubMed
Chang, C. H., Tsai, W. C., Hsu, Y. H., & Pang, J. H. (2020). "Pentadecapeptide BPC 157 accelerates collagen turnover in the healing of the transected rat Achilles tendon." J Orthop Res, 28(5), 655–662. PubMed
Vukojevic, J., Stambolija, V., Stancic-Rokotov, D., et al. (2022). "Pentadecapeptide BPC 157 and the nitric oxide system: a comprehensive review." Prog Neurobiol, 184, 102083. PubMed
Sikiric, P., Seiwerth, S., Grabarevic, Z., et al. (2018). "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal healing." Curr Pharm Des, 24(18), 1990–2001. PubMed
U.S. Food and Drug Administration. (2023). "Pharmacy Compounding Guidance. FDA Category 2 List." FDA.gov

For educational and research purposes only. This is not medical advice. Consult a licensed healthcare provider before considering any peptide. BPC-157 is not FDA-approved for any medical indication in humans and was added to the FDA Category 2 list in September 2023, making it ineligible for pharmacy compounding in the United States. The published human evidence base is extremely limited (roughly three small pilot studies). The bulk of supporting data is preclinical and cannot be reliably extrapolated to human safety or efficacy. Information current as of May 2026. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does.